BLRX is trading 11% down at $2.81 as broader market weakness and risk-off sentiment in the small-cap biotech sector outweigh positive clinical news.
- BioLineRx released new preclinical data showing strong synergy between its GLIX1 asset and PARP inhibitors in ovarian cancer.
- The stock is giving back recent gains tied to GLIX1 trial milestones and remains highly volatile in a cautious macro environment.